Contribute Try STAT+ Today

Loxo Oncology has earned considerable buzz and a hefty stock market valuation for bringing a genomic-based approach to cancer drug development. The Connecticut biotech’s drugs target highly specific genetic mutations found in cancer cells, regardless of where in the body the tumor is located.

The first of Loxo’s experimental drugs, larotrectinib, has already demonstrated a strong cancer-killing ability in tumors with a genetic alteration called a TRK gene fusion. The drug is under FDA review with an approval decision expected in late November.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.